Study S001827

The Benefit of a Liraglutide-based Weight Management Alone or in Addition to Standard CPAP Therapy on Metabolic Function in Patients With Obstructive Sleep Apnoea (OSA) - an Explorative, Proof-of-concept Study

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04186494
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: SINGLE
Status: COMPLETED
Enrollment: 30
Start: 2019-12-02
Primary completion: 2021-12-31
Lead sponsor: St Vincent's University Hospital, Ireland
Conditions: Sleep Apnea, Obstructive
Interventions: DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml; DEVICE:Continuous positive airway pressure treatment; COMBINATION_PRODUCT:Liraglutide and CPAP
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Insulin resistance [6 months]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016525	Effect of Liraglutide on Intermittent Hypoxia-Induced Metabolic Dysfunction: From Bench to Bedside. O'Donnell C, Journal of sleep research	2026	Randomized trial	PMID 40718907 DOI	cites ClinicalTrials.gov:NCT04186494
R0026367	Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study. O'Donnell C, Annals of the American Thoracic Society	2024	Randomized trial	PMID 38096106 DOI	cites ClinicalTrials.gov:NCT04186494; registry reference DERIVED:38096106
R0044283	Evaluating a new treatment approach for obstructive sleep apnoea in adults with obesity and without diabetes: a proof-of-concept study investigating the effects of glucagon-like-peptide-1 agonist-mediated weight loss versus CPAP or both in combination, on metabolic, cardiovascular and quality of life outcomes Cliona P O'Donnell, Research Repository UCD (University College Dublin)	2024	Randomized trial		cites ClinicalTrials.gov:NCT04186494
R0025517	Continuous positive airway pressure but not Liraglutide-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: Data from a randomized proof-of-concept study O’Donnell C, medRxiv	2023	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04186494
R0050781	Liraglutide-Based Weight Loss versus CPAP Therapy in improving Sleep Quality and Quality of Life of Patients with Obstructive Sleep Apnoea - an Explorative, Proof of Concept Study Cliona O’Donnell	2023	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04186494
R0053367	The effect of CPAP therapy on coronary artery plaque volume in obstructive sleep apnoea: data from a proof-of-concept study Cliona O’Donnell	2023	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04186494
R0048082	The effect of CPAP therapy on aortic inflammation in obstructive sleep apnoea: data from a proof-of-concept PET-CT study Colm P. O’Donnell, 04.02 - Clinical and epidemiological respiratory sleep medicine	2022	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04186494